ready for liftoff

Photos: The Cannon Houston's downtown space expects to open its doors early next month

The Cannon Houston's third location is planned to open on December 9. Photo courtesy of The Cannon

A Houston entrepreneurial hub plans to open its third coworking space location only a few weeks after its main campus debuted in West Houston.

The Cannon Houston's newest location will be a 17,000-square-foot space on the top floor of The Cannon Tower at Amegy on Main in Downtown Houston. The opening date for the new space is Monday, December 9.

The announcement follows the grand opening of The Cannon's 120,000-square-foot flagship space, which is now close to being completely leased by startups and small businesses, and represents another step in the company's ambitious expansion plan.

"We've long known that we will need multiple locations across Houston in order to serve our mission of supporting Houston's entrepreneurs, and we are thrilled to work with an incredibly forward-thinking organization like Amegy to continue to fulfill this mission," says Cannon founder and president, Lawson Gow, in a news release. "The Cannon Tower at Amegy on Main will be unlike any other space in the city, in which we will be developing a 'vertical village' of innovation, programs, and resources, transforming Amegy on Main into a hub for Downtown Houston's entrepreneurs."

Gow — who is the son of David Gow, owner of InnovationMap's parent company, Gow Media — recently transitioned into his position as The Cannon named Jon Lambert as CEO earlier this month.

The Cannon's space is just one part of the equation that is the Downtown Launch Pad — a joint project between Central Houston, Downtown Redevelopment Authority, The Cannon, and Amegy Bank. The Amegy building will also house MassChallenge and gener8or, as well as event and common space for programming on the 11th floor.

"Amegy Bank is thrilled to be a part of the expansion of the innovation community by offering space, amenities, and business development support," says Kelly Foreman, Amegy Bank's senior vice president and manager of corporate real estate and facilities, in a news release. "We have a long track record of helping businesses grow, and creating this space for a hub of start-ups and accelerators is yet another way to do just that."

Moving forward, The Cannon will play a role in expanding workspace, resources, and programming in the building. The space is now open for leasing, and the first 100 members to join the new space will receive free parking for the course of their membership.

Workspace for everyone

Photo courtesy of The Cannon

Leasing opportunities range so that there's something for everyone.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted